WHERE ARE WE TODAY? Professor Dr med Ulrich Mrowietz Academy - - PowerPoint PPT Presentation

WHERE ARE WE TODAY?

Professor Dr med Ulrich Mrowietz

• HCPs who already have a patient empowering

approach to treatment

• HCPs who will take responsibility in rolling out

the implementation of different tools and programs to improve patient adherence and

• utcomes nationally
• HCPs who are collaborative, contributing and

forward-thinking

• HCPs who can communicate in English

Professionals who not only get inspired but who are willing to make a difference

Academy participant profile

Key objectives of the Academy

• Support implementation of patient empowerment in daily

clinical practice

• Disseminate tools or interventions that will help improve

patient adherence (and thus patient outcomes) without increasing overall time and cost per patient

• Support improvement of HCP and patient communication
• Build a platform for a continuous communication loop with

participants through interactions and support

To enhance adherence and real-life

• utcomes for people living with psoriasis

Communication is key

• How we communicate information to patients about their

disease and treatments is key to improving adherence:

• The Psoriasis Academy aims to equip you to teach others

about communication strategies that improve adherence

• The Academy will offer training, resources and processes

that support HCPs to empower their patients to take control

• f their condition

Informed and engaged patients stand a better chance of managing their psoriasis effectively Patients can be empowered through interaction and communication with their HCP

Identifying specific adherence challenges

Research identified four basic patient types in psoriasis Self-manager Actively engaged Why me? Help me

40% 16% 28% 16%

Based on insights from Bewley et al. J Eur Acad Dermatol Venereol 2014;28:763–770

Understanding these patient types may benefit HCP–patient communication

• Grouping patients according to key behaviours

and characteristics will support HCPs in their engagement with patients, helping them to:

• Refer patients as necessary for psychological

assessment/therapy

• Provide empathy, emotional support and

educational resources

• To use medication more efficiently

Understanding these patient types may benefit HCP–patient communication

• Research indicates that patients belonging to

the ‘Why me’ and ‘Help me’ profile types*:

• May have a more negative relationship with their HCP
• Tend to be the least satisfied with topical treatments

(due to onset of action, and fear of side effects)

• ‘Help me’ profile may have more concomitant conditions

and have a greater propensity to anxiety, depression, insomnia and arthritis

*Based on research insights (5+ years, ~6000 patients), data for 1884 of these patients published in Bewley et al. J Eur Acad Dermatol Venereol 2014;28:763–770

Understanding these patient types may benefit HCP–patient communication

• A good HCP–patient relationship and

inclusion of patients in therapy decisions (joint planning approach) may help to improve treatment adherence and patient satisfaction1,2

• This requires sufficient time at each visit to

explain the use, benefits and possible side effects of medications

• 1. Augustin et al. Dermatology 2011;222:363−374; 2. Umar et al. J Eur Acad Dermatol Venereol 2013;27:763−770

HCP–patient interactions

Expectations/understanding influence treatment adherence

Differences in HCP and patient expectations/ understanding are:

• Treatment goals
• Need for education
• Content and quality of first visit
• Importance of maintenance treatment

Uhlenhake et al. J Dermatolog Treat 2010;21:6–12

HCP–patient interactions

Expectations/understanding influence treatment adherence

Improving the HCP–patient relationship can improve medication adherence:1,2

• A patient’s trust in a HCP is linked with effective

communication

• Trust can be increased if HCPs:
• Show patients they understand the burden
• f their illness
• Listen to patients’ concerns
• Physically examine patients’ skin
• 1. Feldman et al. J Am Acad Dermatol 2008;59:1009–1016; 2. Feldman SR. J Drugs Dermatol 2010;9:908–911

Summary (1)

• Treatment adherence is recognised as a

specific challenge to the effective treatment

• f inflammatory skin conditions such as

psoriasis

• Non-adherence to treatment is associated

with poor clinical outcomes, may foster inappropriate therapeutic decisions and can result in increased healthcare costs

Summary (2)

• There are many reasons for patients not

adhering to treatment, both intentional and non-intentional:

Social and economic HCP and system related Disease related Treatment related Patient related

National roll-outs

Delegates from 29 countries attended the 3 regional Academies Most countries have held or are planning their faculty meetings >20 countries have held national academy workshops

Reaching over 1600 healthcare professionals